The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS

Neurology

Volumn 66, Issue 2, 2006, Pages 275-277

  Pöllmann, Walter ^a   Erasmus, Lutz Peter ^b   Feneberg, Wolfgang ^a   Straube, Andreas ^b  

^a Marianne Strauss Hospital   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; LIVER ENZYME; MITOXANTRONE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; ARTICLE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SKIN TOXICITY; SYNCOPE; TENSION HEADACHE; ULCERATIVE COLITIS; VISUAL ANALOG SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INCIDENCE; MIDDLE AGED; TIME;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HEADACHE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; TIME FACTORS;

EID: 33644919972     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000194317.75449.91     Document Type: Article

References (10)

1. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002;162:2161-2169.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
3. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology 1999;53:679-686.
4. PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-1636.
5. D'Amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia 2004;24:980-984.
6. Pöllmann W, Erasmus L-P, Feneberg W, Then Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002;59:636-639.
7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 (suppl 7):1-96.
8. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappa B as a molecular target for migraine therapy. Ann Neurol 2002;51:507-516.
9. Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, Pfeffer LM. IFN alpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci USA 2000;97:13631-13636.
10. Li QQ, Burt DR, Bever CT. Glatiramer acetate inhibition of tumor necrosis factor-alpha-induced RANTES expression and release from U-251 MG human astrocytic cells. J Neurochem 2001;77:1208-1217.